Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 ... announced the addition of the "Global Smart ... report to their offering.      (Logo: ... Wearable Healthcare Devices and Services market to grow ... 2015-2019 The report covers the present ...
(Date:3/26/2015)... 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" ... patent acceptance notice from the Israeli patent office with ... or reduce tissue damage caused by an increase in ... vessels are opened after a blockage causing a heart ... Damage can be caused to the heart ...
(Date:3/26/2015)... N.J. , March 26, 2015  Becton, Dickinson ... that it will commence offers to exchange all validly ... by CareFusion Corporation, a wholly owned subsidiary of BD, ... in the table below. A Registration Statement on Form ... the New Notes was filed with the Securities and ...
Breaking Medicine Technology:Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5
... samples to be used to identify molecular,signature of ... ALS Therapy,Development Institute (ALS TDI) announced today ... samples collected through an expanded network,of clinical partnerships. ... effort to indentify the altered expression of genes,and ...
... Vical Incorporated,(Nasdaq: VICL ) today ... a leading European medical university, and the ... governmental expert agency, to,evaluate Vical,s Vaxfectin(R) adjuvant ... Medical Technologies Inc.,OTCBB:BJCT) for a multivalent preventive ...
Cached Medicine Technology:ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5
(Date:3/26/2015)... MALVERN, PA (PRWEB) March 26, 2015 ... leading providers of continuing medical education, the ... for Culinary Medicine at Tulane University are ... in Culinary Medicine. The interdisciplinary program ... Specialist (CCMS) credential, is designed for physicians, nurse ...
(Date:3/26/2015)... “The SWEET Act is an important step to ... and help parents who are working to reduce sugar in ... to support public health, and we will continue to stand ... of all families,” said Dr. Jane Delgado President and CEO ... of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa ...
(Date:3/26/2015)... Saving Moses is a global humanitarian ... needed but least available. As one of their staple ... in the Benguela province of Angola to treat babies ... visit to their clinics, staff employed the art of ... babies in a nation the The New York Times ...
(Date:3/26/2015)... Frencisco, CA (PRWEB) March 26, 2015 ... Center are proud to announce expanded offerings for Bay ... San Francisco Dental Implant Center has long been a ... have expanded its offerings to meet the strong demand ... in our reputation as a top-rated dental implant facility ...
(Date:3/26/2015)... San Juan Capistrano, Calif. (PRWEB) March 26, 2015 ... monitoring equipment and repairs, is pleased to be featured ... the Discovery Channel on March 18, 2015. The ... status, and it is live on the Pacific Medical ... families that face life threatening emergencies, it is reassuring ...
Breaking Medicine News(10 mins):Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Saving Moses Utilized Photography in an Effort to Engage Mothers and Their Babies on a Recent Visit to Angola 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3
... But Canadian study finds increase in non-serious side effects ... contain compounds called cannabinoids from the marijuana plant don,t ... associated with an increase in some non-serious side effects, ... in Montreal and the University of British Columbia (UBC) ...
... its wholly-owned subsidiary Embryome Sciences, Inc. announced ... International Embryome Initiative, an international collaboration with ... first systematic map of all the cell ... In a paper published today titled “The ...
... cellular ... analysis capabilities, ... a leader in innovative solutions for drug discovery and ... (Sunnyvale, CA) for $13 million. The acquisition,of Blueshift Biotechnologies, ...
... latest,report by the American Lung Association, Lung Disease Data, ... death rates due to other,leading causes of death such ... pulmonary disease (COPD) is expected to,become the third leading ... Association publishes Lung Disease Data to serve as a,resource ...
... Accelera Recognised as Key Partner in the Development of ... treatment of African,trypanosomiasis, commonly known as "sleeping sickness", by ... business unit of,Nerviano Medical Sciences (NMS), is to be ... The award will be conferred today in New York, ...
... Community in Hydration and Sanitation, Sand Bag , ... ... students assisted Missouri community residents who were impacted by raging ... students ensured that Clarksville families were educated on proper sanitation, the ...
Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 3Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 4Health News:MDS Analytical Technologies Acquires Blueshift Biotechnologies 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 3Health News:The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness" 2Health News:Sanford-Brown College Students Help in Missouri Flood Relief 2
... is part of a series of modular systems ... from 3.5 to 8.0 mm. Matching a combination ... provides convenience and flexibility for the orthopaedic surgeon ... may be customized using two of three screw ...
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
... a complete system of surgical instruments and ... fusion surgery. The system was designed in ... research and engineering with advanced materials, techniques ... different, and because the anatomy of the ...
... The Retrograde Humeral Nail enables fixation ... shoulder symptoms that may be associated with ... enables proximal and distal interlocking using a ... for posterior-anterior interlocking with the patient in ...
Medicine Products: